Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir in HCV Genotype 1, 4, 5 and 6 Patients on Dialysis for End Stage Renal Disease
2016-003489-25Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2017
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Harvoni in chronic hepatitis C (CHC) and hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Jan 2017; status: completed.
02
Drugs
Harvoni
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2016-003489-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003489-25.